These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 38474208)

  • 1. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
    Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
    Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY
    Kloock S; Haerting N; Herzog G; Oertel M; Geiger N; Geier A; Sequeira V; Nickel A; Kohlhaas M; Fassnacht M; Dischinger U
    Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity.
    McGlone ER; Hope DCD; Davies I; Dore M; Goldin R; Jones B; Liu Z; Li JV; Vorkas PA; Khoo B; Carling D; Minnion J; Bloom SR; Tan TM
    Biomed Pharmacother; 2024 Jul; 176():116888. PubMed ID: 38861859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Semaglutide Modulates Extracellular Matrix Production of LX-2 Cells via Exosomes and Improves Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Scavo MP; Lisco G; Depalo N; Rizzi F; Volpe S; Arrè V; Carrieri L; Notarnicola M; De Nunzio V; Curri ML; De Pergola G; Piazzolla G; Giannelli G
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beneficial effect of oral semaglutide for type 2 diabetes mellitus in patients with metabolic dysfunction-associated steatotic liver disease: A prospective, multicentre, observational study.
    Arai T; Atsukawa M; Tsubota A; Oikawa T; Tada T; Matsuura K; Ishikawa T; Abe H; Kato K; Morishita A; Tani J; Okubo T; Nagao M; Iwabu M; Iwakiri K
    Diabetes Obes Metab; 2024 Nov; 26(11):4958-4965. PubMed ID: 39223865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease.
    Soresi M; Giannitrapani L
    World J Gastroenterol; 2024 Aug; 30(30):3541-3547. PubMed ID: 39193573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Semaglutide alters gut microbiota and improves NAFLD in db/db mice.
    Mao T; Zhang C; Yang S; Bi Y; Li M; Yu J
    Biochem Biophys Res Commun; 2024 May; 710():149882. PubMed ID: 38583231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.
    Pontes-da-Silva RM; de Souza Marinho T; de Macedo Cardoso LE; Mandarim-de-Lacerda CA; Aguila MB
    Int J Obes (Lond); 2022 Jan; 46(1):21-29. PubMed ID: 34465857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver sympathetic denervation reverses obesity-induced hepatic steatosis.
    Hurr C; Simonyan H; Morgan DA; Rahmouni K; Young CN
    J Physiol; 2019 Sep; 597(17):4565-4580. PubMed ID: 31278754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mTORC1/AMPK pathway plays a role in the beneficial effects of semaglutide (GLP-1 receptor agonist) on the liver of obese mice.
    Reis-Barbosa PH; Marcondes-de-Castro IA; Marinho TS; Aguila MB; Mandarim-de-Lacerda CA
    Clin Res Hepatol Gastroenterol; 2022; 46(6):101922. PubMed ID: 35427802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-Inflammation and De Novo Lipogenesis Markers Are Involved in Metabolic Associated Fatty Liver Disease Progression in BTBR ob/ob Mice.
    Opazo-Ríos L; Soto-Catalán M; Lázaro I; Sala-Vila A; Jiménez-Castilla L; Orejudo M; Moreno JA; Egido J; Mas-Fontao S
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Yamasaki Y; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Dec; 26(12):5982-5994. PubMed ID: 39344853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.
    Kakegawa T; Sugimoto K; Saito K; Yunaiyama D; Araki Y; Wada T; Takahashi H; Yoshimasu Y; Takeuchi H; Itoi T
    Medicine (Baltimore); 2024 Jun; 103(23):e38444. PubMed ID: 38847728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease.
    Domingues I; Yagoubi H; Zhang W; Marotti V; Kambale EK; Vints K; Sliwinska MA; Leclercq IA; Beloqui A
    Drug Deliv Transl Res; 2024 Oct; 14(10):2917-2929. PubMed ID: 38615156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipidomic Analysis Reveals Alterations in Hepatic FA Profile Associated With MASLD Stage in Patients With Obesity.
    Núñez-Sánchez MÁ; Martínez-Sánchez MA; Martínez-Montoro JI; Balaguer-Román A; Murcia-García E; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez-Cáceres CM; Sledzinski T; Frutos MD; Hernández-Morante JJ; Fernández-García JC; Queipo-Ortuño MI; Ruiz-Alcaraz AJ; Mika A; Ramos-Molina B
    J Clin Endocrinol Metab; 2024 Jun; 109(7):1781-1792. PubMed ID: 38217869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palmitoleic Acid Decreases Non-alcoholic Hepatic Steatosis and Increases Lipogenesis and Fatty Acid Oxidation in Adipose Tissue From Obese Mice.
    Cruz MM; Simão JJ; de Sá RDCC; Farias TSM; da Silva VS; Abdala F; Antraco VJ; Armelin-Correa L; Alonso-Vale MIC
    Front Endocrinol (Lausanne); 2020; 11():537061. PubMed ID: 33117273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.